Cylene Pharmaceuticals, Inc.

Cylene Pharmaceuticals, Inc. (Cylene) is a privately held clinical-stage biotechnology company. It is principally engaged in the discovery, development and commercialization of targeted small-molecule drugs used in the treatment of life-threatening cancers. The company products are created based on its two internal proprietary discovery platforms, among which one of the discovery platforms is in used in designing novel Nucleolus Targeting Agents (NTAs), and the second discovery platform is used in creating first-in-class Serine/Threonine protein kinase inhibitors. Cylene product pipeline include Oral CX-4945, Quarfloxin (CX-3543) and Oral CX-5461. Its products target the abnormal nucleolus functions of cancer cells and selectively kill cancer cells, thus by which they help in curing cancer. The development program of Cylene include Quarfloxin, which is in its phase II C/NET study. The company is headquartered at San Diego in California, the US.

Street: 
5820 Nancy Ridge Drive
City: 
San Diego
Postcode: 
92121
Federal State : 
United States
WebSite: 
www.cylenepharma.com
Fax: 
1-858-8755101

Company Index Score

Current Index Score Historical Index Score
  • Cylene Pharmaceuticals, Inc. currently scores 50 % in the index.
  • Cylene Pharmaceuticals, Inc. is currently ranked equal 15 out of a total of 35419 included in the NS Company Index. This is the top 0.042 % of all companies.
  • Cylene Pharmaceuticals, Inc. is currently ranked 3 out of 8430 companies. This is in the top 0.036 % percent of Healthcare companies ranked in the index.
  • User perception of the company stands at 0 % percent. This differs 50 % percent over the score attributed to the company by other scoring factors.

Latest tweets